Compare OFLX & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OFLX | HELP |
|---|---|---|
| Founded | 1975 | N/A |
| Country | United States | Canada |
| Employees | N/A | 50 |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 299.4M | 279.9M |
| IPO Year | 2005 | N/A |
| Metric | OFLX | HELP |
|---|---|---|
| Price | $31.22 | $4.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $51.50 |
| AVG Volume (30 Days) | 34.3K | ★ 610.6K |
| Earning Date | 04-29-2026 | 07-01-2026 |
| Dividend Yield | ★ 4.05% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $98,296,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $148.48 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.58 | $3.76 |
| 52 Week High | $37.92 | $8.55 |
| Indicator | OFLX | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 57.63 | 36.62 |
| Support Level | $26.51 | N/A |
| Resistance Level | $31.47 | $4.75 |
| Average True Range (ATR) | 1.05 | 0.26 |
| MACD | 0.29 | -0.04 |
| Stochastic Oscillator | 86.75 | 24.29 |
Omega Flex Inc is a manufacturer of flexible metal hoses, which is used in a variety of ways to carry gases and liquids within their particular applications. Omega sells its products under the TracPipe, CounterStrike, DoubleTrac, DEF-Trac and MediTrac brands. It serves various markets which include construction, manufacturing, transportation, petrochemical, pharmaceutical, and other industries. Geographically Omega Flex, Inc operates in the United States. The company derives revenues from the manufacture and sale of flexible metal hose and accessories.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.